DNLI – Denali Therapeutics Inc.
Denali Therapeutics Inc.DNLI
$28.63Name : Denali Therapeutics Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $4,098,813,696.00
EPSttm : -2.86
Denali Therapeutics Inc.
$28.63
1.45%$0.41Fair Value
Margin Of Safety %
Put/Call OI Ratio
0.73
Float Short %
7.89
EPS 1 Diff
-0.04
EPS Year Diff
-1.47
Ticker: DNLI
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2024-09-06 | DNLI | 25.21 | 0.40 | 0.36 | 3516 |
| 2024-09-09 | DNLI | 25.52 | 0.40 | 0.00 | 3529 |
| 2024-09-10 | DNLI | 26.33 | 0.40 | 0.00 | 3535 |
| 2024-09-11 | DNLI | 27.08 | 0.40 | 0.00 | 3536 |
| 2024-09-12 | DNLI | 27.98 | 0.40 | 0.00 | 3538 |
| 2024-09-13 | DNLI | 30.78 | 0.38 | 0.05 | 3614 |
| 2024-09-16 | DNLI | 30.37 | 0.37 | 0.02 | 3753 |
| 2024-09-17 | DNLI | 30.67 | 0.37 | 0.00 | 3763 |
| 2024-09-18 | DNLI | 30.78 | 0.37 | 0.19 | 3763 |
| 2024-09-19 | DNLI | 31.08 | 0.37 | 0.00 | 3766 |
| 2024-09-20 | DNLI | 30.9 | 0.47 | 0.40 | 4420 |
| 2024-09-23 | DNLI | 30.23 | 0.79 | 0.10 | 1539 |
| 2024-09-24 | DNLI | 30.34 | 0.78 | 0.00 | 1548 |
| 2024-09-25 | DNLI | 28.95 | 0.76 | 0.35 | 1570 |
| 2024-09-26 | DNLI | 29.19 | 0.76 | 0.00 | 1581 |
| 2024-09-27 | DNLI | 29.43 | 0.76 | 0.00 | 1582 |
| 2024-09-30 | DNLI | 29.13 | 0.76 | 0.67 | 1584 |
| 2024-10-01 | DNLI | 28.66 | 0.76 | 0.00 | 1585 |
| 2024-10-02 | DNLI | 29.03 | 0.76 | 0.00 | 1585 |
| 2024-10-03 | DNLI | 28.19 | 0.75 | 0.24 | 1595 |
| 2024-10-04 | DNLI | 28.66 | 0.73 | 3.00 | 1642 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2024-09-06 | DNLI | 25.25 | 15.3 | 212.6 | -2.53 |
| 2024-09-09 | DNLI | 25.60 | 15.3 | 207.1 | -2.53 |
| 2024-09-10 | DNLI | 26.34 | 15.3 | 202.1 | -2.53 |
| 2024-09-11 | DNLI | 27.08 | 15.3 | 202.2 | -2.53 |
| 2024-09-12 | DNLI | 27.97 | 15.3 | 200.5 | -2.53 |
| 2024-09-13 | DNLI | 30.80 | 15.3 | 176.0 | -2.53 |
| 2024-09-16 | DNLI | 30.37 | 15.3 | 216.9 | -2.53 |
| 2024-09-17 | DNLI | 30.68 | 15.3 | 208.3 | -2.53 |
| 2024-09-18 | DNLI | 30.78 | 15.3 | 211.2 | -2.53 |
| 2024-09-19 | DNLI | 31.08 | 15.3 | 208.7 | -2.53 |
| 2024-09-20 | DNLI | 30.92 | 15.3 | 214.2 | -2.53 |
| 2024-09-23 | DNLI | 30.24 | 15.3 | 220.1 | -2.53 |
| 2024-09-24 | DNLI | 30.33 | 15.3 | 211.3 | -2.53 |
| 2024-09-25 | DNLI | 28.99 | 15.3 | 227.8 | -2.53 |
| 2024-09-26 | DNLI | 29.27 | 15.3 | 209.1 | -2.53 |
| 2024-09-27 | DNLI | 29.43 | 15.3 | 210.4 | -2.53 |
| 2024-09-30 | DNLI | 29.12 | 15.3 | 215.7 | -2.53 |
| 2024-10-01 | DNLI | 28.67 | 15.3 | 218.0 | -2.53 |
| 2024-10-02 | DNLI | 29.03 | 15.3 | 208.1 | -2.53 |
| 2024-10-03 | DNLI | 28.22 | 15.3 | 222.2 | -2.53 |
| 2024-10-04 | DNLI | 28.63 | 15.3 | 207.2 | -2.53 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2024-09-06 | DNLI | -0.72 | -0.74 | 7.03 |
| 2024-09-09 | DNLI | -0.72 | -0.74 | 7.03 |
| 2024-09-10 | DNLI | -0.72 | -0.74 | 7.03 |
| 2024-09-11 | DNLI | -0.72 | -0.74 | 7.03 |
| 2024-09-12 | DNLI | -0.72 | -0.74 | 7.57 |
| 2024-09-13 | DNLI | -0.72 | -0.74 | 7.57 |
| 2024-09-16 | DNLI | -0.72 | -0.74 | 7.57 |
| 2024-09-17 | DNLI | -0.73 | -0.74 | 7.57 |
| 2024-09-18 | DNLI | -0.73 | -0.74 | 7.57 |
| 2024-09-19 | DNLI | -0.73 | -0.74 | 7.57 |
| 2024-09-20 | DNLI | -0.72 | -0.74 | 7.57 |
| 2024-09-23 | DNLI | -0.72 | -0.74 | 7.57 |
| 2024-09-24 | DNLI | -0.72 | -0.74 | 7.57 |
| 2024-09-25 | DNLI | -0.72 | -0.74 | 7.89 |
| 2024-09-26 | DNLI | -0.72 | -0.74 | 7.89 |
| 2024-09-27 | DNLI | -0.72 | -0.74 | 7.89 |
| 2024-09-30 | DNLI | -0.72 | -0.74 | 7.89 |
| 2024-10-01 | DNLI | -0.72 | -0.74 | 7.89 |
| 2024-10-02 | DNLI | -0.84 | -0.74 | 7.89 |
| 2024-10-03 | DNLI | -0.46 | -0.74 | 7.89 |
| 2024-10-04 | DNLI | -0.46 | -0.74 | 7.89 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-0.59
Avg. EPS Est. Current Quarter
-0.61
Avg. EPS Est. Next Quarter
-0.63
Insider Transactions
-0.46
Institutional Transactions
-0.74
Beta
1.38
Average Sales Estimate Current Quarter
9
Average Sales Estimate Next Quarter
8
Fair Value (Academic)
Quality Score
21
Growth Score
31
Sentiment Score
39
Actual DrawDown %
69.5
Max Drawdown 5-Year %
-84
Target Price
40.21
P/E
Forward P/E
PEG
P/S
3227.3
P/B
2.95
P/Free Cash Flow
EPS
-2.85
Average EPS Est. Cur. Y
-2.53
EPS Next Y. (Est.)
-2.68
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-33121.86
Relative Volume
0.37
Return on Equity vs Sector %
-51.9
Return on Equity vs Industry %
-73
EPS 1 7Days Diff
EPS 1 30Days Diff
EBIT Estimation
207.2
Denali Therapeutics Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 364
Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.
stock quote shares DNLI – Denali Therapeutics Inc. Stock Price stock today
news today DNLI – Denali Therapeutics Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch DNLI – Denali Therapeutics Inc. yahoo finance google finance
stock history DNLI – Denali Therapeutics Inc. invest stock market
stock prices DNLI premarket after hours
ticker DNLI fair value insiders trading